Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Gossamer Bio's updated model now points to a fair value of $95.40, up from $82.48, which marks a meaningful shift in the price target assumptions for the stock. Recent Street research links these higher targets to differing views on seralutinib, the regulatory path and how much risk investors should assign to the Phase 3 PROSERA miss and upcoming FDA review. As you read on, you will see how these changing inputs shape the evolving Gossamer Bio narrative and what to watch next.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Gossamer Bio.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Chardan initiated coverage of Gossamer Bio with a Buy rating and a US$160 price target. The firm highlights seralutinib and the potential for FDA approval as the central driver of its upside view.

• Chardan describes the set up as a "highly asymmetric risk/reward" and names Gossamer Bio its top small cap pick for 2027. That puts considerable emphasis on the company's execution around the seralutinib regulatory path.

• Leerink upgraded Gossamer Bio to Outperform with an unchanged US$1 pre split target after management's FDA regulatory update and reacquisition of seralutinib rights. The firm cites comfort that regulators are open to reviewing the totality of the seralutinib data package rather than focusing only on the PROSERA topline miss.

🐻 Bearish Takeaways

• Piper Sandler reduced its target to US$4 from US$15 and kept an Overweight rating. The firm points to the Phase 3 PROSERA statistical outcome as a review issue and underlines that FDA assessment of seralutinib's effect size and significance remains a key execution risk.

• Across these updates, valuation hinges on how regulators assess PROSERA alongside TORREY and other analyses. Any outcome that assigns higher risk to the seralutinib data could weigh on Gossamer Bio's long term growth story.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 4 risks for Gossamer Bio. See which could impact your investment.

What's in the News

• Gossamer Bio submitted its first New Drug Application to the FDA in September 2026 for seralutinib in pulmonary arterial hypertension, backed by the Phase 3 PROSERA study, Phase 2 TORREY confirmatory evidence and supportive analyses following a Pre NDA Type B meeting in June 2026.

• The FDA is expected to decide whether to accept the seralutinib NDA for filing after its initial review, then evaluate the efficacy and safety data during the full NDA review process.

• Gossamer Bio completed a 1 for 80 reverse stock split of its common stock and a proportionate reduction in authorized shares, effective September 10, 2026, with a related stock split event recorded on September 11, 2026.

• The company updated its capital structure and governance through an August 20, 2026 securities purchase agreement for multiple series of convertible preferred stock and pre funded warrants, and an amended and restated bylaw that lowered the regular stockholder meeting quorum to one third of voting power.